LOGO
LOGO

Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
compass 05012026 lt

Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst related to its lead drug candidate Tovecimig in patients with advanced biliary tract cancer, to watch this quarter.

Tovecimig is designed to simultaneously block Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to tumor blood vessel formation.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.